Form 8-K Fusion Pharmaceuticals For: Mar 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Morgan Stanley Downgrades Fusion Pharmaceuticals (FUSN) to Equalweight
March 19, 2024 2:40 PM EDTMorgan Stanley analyst Matthew Harrison downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Overweight to Equalweight with a price target of $21.00 (from $10.00).
The analyst comments "Fusion to be acquired by AstraZeneca for $21/share in cash payable at deal closing (vs. 03/18 closing price of $10.64),... More
Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to Hold
March 19, 2024 10:00 AM EDTJefferies analyst Suji Jeong downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Buy to Hold with a price target of $21.00 (from $10.00).
The analyst comments "AZN will acquire FUSN's radiopharma platform for $21/sh in cash (~$2B upfront), plus another $3/sh CVR (~$400M value) upon... More
